FUL - H.B. Fuller Company
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) today released the below statement regarding H.B. Fuller Company (NYSE: FUL) (“H.B. Fuller” or the “Company”) and Advanced Medical Solutions Group plc (“AMS”). Previously, Ancora issued a letter to H.B. Fuller's Board of Directors (the “Board”) regarding its contemplated acquisition of AMS. Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President.
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday.
Shares in Advanced Medical Solutions Group (AIM:AMS) rose 16% to 278.14p after the company agreed to a recommended cash takeover by H.B. Fuller, the US adhesives group, valuing it at about £659 million.
U.S.-based adhesives maker H.B. Fuller will buy Advanced Medical Solutions Group in a cash deal that values the British medical supplier at about £715 million ($942.1 million) including debt, the companies said on Thursday.
ST. PAUL, Minn.--(BUSINESS WIRE)--H.B. Fuller Company (“H.B. Fuller” or “the Company”) (NYSE: FUL), the world's largest pureplay adhesives company, today announced it has made a recommended cash offer to acquire Advanced Medical Solutions Group plc (“AMS”) (LSE:AMS). “This transaction is a rare opportunity to advance the evolution of our portfolio.” said Celeste Mastin, President and CEO of H.B. Fuller. “We have long been clear that medical is a core strategic growth market for H.B. Fuller give.
The headline numbers for H. B. Fuller (FUL) give insight into how the company performed in the quarter ended May 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
H. B. Fuller (FUL) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.18 per share a year ago.
ST. PAUL, Minn.--(BUSINESS WIRE)--H.B. Fuller Company (NYSE: FUL) today reported financial results for its second quarter that ended May 30, 2026. Second Quarter 2026 Noteworthy Items: Net revenue was $950 million, up 5.8% year-on-year; organic revenue was up 2.6% year-on-year; Gross margin was 33.6%; adjusted gross margin of 34.2% increased 200 basis points year-on-year driven mainly by pricing execution and restructuring savings; Net income was $68 million; adjusted EBITDA was $181 million, u.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
H. B. Fuller (FUL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors looking for stocks in the Chemical - Specialty sector might want to consider either H. B. Fuller (FUL) or Novozymes A/S (NVZMY).
Besides Wall Street's top-and-bottom-line estimates for H. B. Fuller (FUL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended May 2026.